Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
This study is ongoing, but not recruiting participants.
Study NCT00887809   Information provided by Memorial Sloan-Kettering Cancer Center

First Received on April 23, 2009.   Last Updated on January 23, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sarcoma
Leiomyosarcoma
Malignant Fibrous
Histiocytoma
Angiosarcoma
Additional conditions recognized in this trial
Hemangiosarcoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Neoplasms, Fibrous Tissue
Neoplasms, Muscle Tissue
Neoplasms, Vascular Tissue
Additional drug interventions recognized in this trial
Bevacizumab
Docetaxel
Gemcitabine
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services